Literature DB >> 30605362

Development of a biodosimeter for radiation triage using novel blood protein biomarker panels in humans and non-human primates.

Robert P Balog1, Rowena Bacher1, Polly Chang1, Michael Greenstein1, Songeeta Jammalamadaka1, Harold Javitz1, Susan J Knox2, Shirley Lee1, Hua Lin1, Thomas Shaler1, Lei Shura2, Paul Stein1, Kathryn Todd1, David E Cooper1.   

Abstract

PURPOSE: In a significant nuclear event, hundreds of thousands of individuals will require rapid triage for absorbed radiation to ensure effective medical treatment and efficient use of medical resources. We are developing a rapid screening method to assess whether an individual received an absorbed dose of ≥2 Gy based on the analysis of a specific panel of blood proteins in a fingerstick blood sample.
MATERIALS AND METHODS: We studied a data set of 1051 human blood samples obtained from radiotherapy patients, normal healthy individuals, and several special population groups. We compared the findings in humans with those from irradiation studies in non-human primates (NHPs).
RESULTS: We identified a panel of three protein biomarkers, salivary alpha amylase (AMY1), Flt3 ligand (FLT3L), and monocyte chemotactic protein 1 (MCP1), which are upregulated in human patients receiving fractionated doses of total body irradiation (TBI) therapy as a treatment for cancer. These proteins exhibited a similar radiation response in NHPs after single acute or fractionated doses of ionizing radiation.
CONCLUSION: Our work provides confidence in this biomarker panel for biodosimetry triage using fingerstick blood samples and in the use of NHPs as a model for irradiated humans.

Entities:  

Keywords:  Radiation biodosimetry; blood biomarkers; human radiotherapy patient studies; immunoassays; point of care test

Year:  2019        PMID: 30605362     DOI: 10.1080/09553002.2018.1532611

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  9 in total

1.  Validation of a biomarker tool capable of measuring the absorbed dose soon after exposure to ionizing radiation.

Authors:  Anna Giovanetti; Raffaella Marconi; Noha Awad; Hala Abuzied; Neveen Agamy; Mohamed Barakat; Cecilia Bartoleschi; Gianluca Bossi; Marco Canfora; Amr A Elsaid; Laura Ioannilli; Horeya M Ismail; Yasmine Amr Issa; Flavia Novelli; Maria Chiara Pardini; Claudio Pioli; Paola Pinnarò; Giuseppe Sanguineti; Mohamed M Tahoun; Riccardo Turchi; Lidia Strigari
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

2.  Serum RNA biomarkers for predicting survival in non-human primates following thoracic radiation.

Authors:  Jared M May; Uma Shankavaram; Michelle A Bylicky; Sunita Chopra; Kevin Scott; Shannon Martello; Karla Thrall; Jim Axtelle; Naresh Menon; C Norman Coleman; Molykutty J Aryankalayil
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

3.  Comparison of Proteomic Expression Profiles after Radiation Exposure across Four Different Species.

Authors:  Mary Sproull; Denise Nishita; Polly Chang; Maria Moroni; Deborah Citrin; Uma Shankavaram; Kevin Camphausen
Journal:  Radiat Res       Date:  2022-04-01       Impact factor: 3.372

Review 4.  Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values.

Authors:  Kuldeep Dhama; Shyma K Latheef; Maryam Dadar; Hari Abdul Samad; Ashok Munjal; Rekha Khandia; Kumaragurubaran Karthik; Ruchi Tiwari; Mohd Iqbal Yatoo; Prakash Bhatt; Sandip Chakraborty; Karam Pal Singh; Hafiz M N Iqbal; Wanpen Chaicumpa; Sunil Kumar Joshi
Journal:  Front Mol Biosci       Date:  2019-10-18

5.  NIH Policies and Regulatory Pathways to U.S. FDA licensure: Strategies to Inform Advancement of Radiation Medical Countermeasures and Biodosimetry Devices.

Authors:  Merriline M Satyamitra; Zulmarie Perez-Horta; Andrea L DiCarlo; David R Cassatt; Carmen I Rios; Paul W Price; Lanyn P Taliaferro
Journal:  Radiat Res       Date:  2022-05-01       Impact factor: 3.372

6.  Circulating Cell-Free DNA Correlates with Body Integral Dose and Radiation Modality in Prostate Cancer.

Authors:  Natalie A Lockney; Randal Henderson; Steven G Swarts; Zhenhuan Zhang; Bingrong Zhang; Jennifer Li; Robert A Zlotecki; Christopher G Morris; Katherine Casey-Sawicki; Paul Okunieff
Journal:  Int J Part Ther       Date:  2020-09-15

Review 7.  The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy.

Authors:  Francisco J Cueto; David Sancho
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

8.  Positive Cofactor 4 as a Potential Radiation Biodosimeter for Early Assessment.

Authors:  Le Ma; Qiang Gong; Gaoyu Liu; Jieping Chen; Yu Wang; Peng Luo; Chunmeng Shi
Journal:  Dose Response       Date:  2022-02-23       Impact factor: 2.658

9.  The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy.

Authors:  Łukasz Kuncman; Magdalena Orzechowska; Konrad Stawiski; Michał Masłowski; Magdalena Ciążyńska; Leszek Gottwald; Tomasz Milecki; Jacek Fijuth
Journal:  Cancers (Basel)       Date:  2022-08-09       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.